"Asthma in children". Asthma
Conditions
Interventions
Intervention 1: Intervention: 5 mg montelukast daily. Intervention 2: Control: fluticasone 100 mcg spray two puffs twice a day.
Treatment - Drugs
Intervention: 5 mg montelukast daily
Control: fluticasone 100 mcg spray two puffs twice a day
Sponsors
"Tabriz University of Medical Sciences, Assistance Research"
Eligibility
Sex/Gender
All
Age
No minimum to 5 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: (no abnormalities underlying anatomic disease? family history of allergies and asthma patient ) And exclusion criteria: (anatomical issues such as the children with Gastroesophageal Reflux Disease? Cystic fibrosis ? underlying medical condition such as cardiovascular problems they are not in the study).
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| "Wheeze intensity". Timepoint: The severity of wheezing diagnosed based on clinical examination and recorded every 2-4 weeks to 6 months after starting treatment with Montelukast 5 mg daily and Fluticasone 100 mcg twice a day, patients are followed up. Method of measurement: Physical examination. | — |
Secondary
| Measure | Time frame |
|---|---|
| "Cough intensity". Timepoint: The severity of coughing diagnosed based on clinical examination and recorded every 2-4 weeks to 6 months after starting treatment with Montelukast 5 mg daily and Fluticasone 100 mcg twice a day, patients are followed up. Method of measurement: Physical examination.;"Dyspnea intensity". Timepoint: The severity of dyspnea diagnosed based on clinical examination and recorded every 2-4 weeks to 6 months after starting treatment with Montelukast 5 mg daily and Fluticasone 100 mcg twice a day, patients are followed up. Method of measurement: Physical examination. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public Contact"Maryam Abbasnazhad"
"Tabriz University of Medical Science"
Outcome results
None listed